Solasia Pharma K.K Yönetim

Yönetim kriter kontrolleri 2/4

Solasia Pharma K.K CEO'su Yoshihiro Arai, Feb2013 tarihinde atandı, in görev süresi 11.75 yıldır. şirketin hisselerinin 0.53% doğrudan sahiptir ve bu hisselerin değeri ¥ 57.73M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 7.1 yıldır.

Anahtar bilgiler

Yoshihiro Arai

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	11.8yrs
CEO sahipliği	0.5%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	7.1yrs

Son yönetim güncellemeleri

Recent updates

CEO

Yoshihiro Arai (64 yo)

11.8yrs

Görev süresi

Mr. Yoshihiro Arai has been the President, Chief Executive Officer and Representative Director at Solasia Pharma KK since February 2013. Mr. Arai served as Executive Vice President of Development of Solasi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yoshihiro Arai	President	11.8yrs	Veri yok	0.53% ¥ 57.7m
Toshio Miyashita	CFO, GM of Management Headquarters & Director	10.8yrs	Veri yok	0.23% ¥ 24.9m
Yasumitsu Shimada	Accounting Manager	no data	Veri yok	Veri yok
Yasuaki Manabe	Head of Marketing Division	4.8yrs	Veri yok	Veri yok
Fumiko Nagahama	Head of Product Development Division	no data	Veri yok	Veri yok
Hikaru Osawa	Head of Production Management Division	2.8yrs	Veri yok	Veri yok
Wataru Kobayashi	Head of Reliability Assurance Division	2.8yrs	Veri yok	Veri yok
Kozo Yao	Head of Business Development Division	less than a year	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 4597 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yoshihiro Arai	President	11.8yrs	Veri yok	0.53% ¥ 57.7m
Toshio Miyashita	CFO, GM of Management Headquarters & Director	8.9yrs	Veri yok	0.23% ¥ 24.9m
Yoshiyuki Yamakawa	Outside Audit & Supervisory Board Member	4.7yrs	Veri yok	Veri yok
Stanley Lau	Independent Outside Director	9.9yrs	Veri yok	Veri yok
Norikazu Eiki	Independent Outside Director	8.6yrs	Veri yok	Veri yok
Susumu Araki	Full-time Outside Audit & Supervisory Board Member	5.7yrs	Veri yok	Veri yok
Jiro Mizukawa	Independent Outside Director	4.7yrs	Veri yok	Veri yok
Nagisa Kawaida	Outside Audit & Supervisory Board Member	less than a year	Veri yok	Veri yok

7.1yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4597 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.1 yıldır).

Solasia Pharma K.K Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Solasia Pharma K.K., Annual General Meeting, Mar 22, 2024

Insufficient new directors

Solasia Pharma K.K., Annual General Meeting, Mar 23, 2023

Solasia Pharma K.K., Annual General Meeting, Feb 24, 2022

Solasia Pharma K.K., Annual General Meeting, Mar 29, 2021

Recent updates

New major risk - Revenue size

Second quarter 2024 earnings released: JP¥1.58 loss per share (vs JP¥1.17 loss in 2Q 2023)

First quarter 2024 earnings released: JP¥1.78 loss per share (vs JP¥1.44 loss in 1Q 2023)

Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New minor risk - Profitability

Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited

Consensus EPS estimates fall by 36%, revenue upgraded

Forecast breakeven date pushed back to 2026

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited

Solasia Pharma K.K., Annual General Meeting, Mar 22, 2024

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 66%

New major risk - Financial position

Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Solasia Pharma K.K. to Report Q2, 2024 Results on Aug 14, 2024

New major risk - Share price stability

Third quarter 2023 earnings released: JP¥1.97 loss per share (vs JP¥4.95 loss in 3Q 2022)

Second quarter 2023 earnings released: JP¥1.17 loss per share (vs JP¥4.38 loss in 2Q 2022)

First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥4.61 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Solasia Pharma K.K., Annual General Meeting, Mar 23, 2023

Solasia Pharma K.K. to Report Fiscal Year 2022 Results on Feb 14, 2023

Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. (TSE:4597) from ITOCHU Corporation (TSE:8001).

Third quarter 2022 earnings released: JP¥4.95 loss per share (vs JP¥5.46 loss in 3Q 2021)

Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Solasia Announces Summary of SP-04 PledOx Development Status

Solasia Announces Summary of SP-04 PledOx Development Status

Solasia Announces Launch of Darvias in Japan

Second quarter 2022 earnings released: JP¥4.38 loss per share (vs JP¥5.67 loss in 2Q 2021)

Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Solasia Pharma K.K. Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin)

Solasia Pharma K.K. announced that it has received ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. announced that it has received ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX).

Solasia Pharma K.K. announced that it expects to receive ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. Announces an Organoarsenic Drug "Darvias® Injection 135Mg" (Sp-02, Hereinafter Darvias®) Has Been Approved for Relapsed or Refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare

First quarter 2022 earnings released: JP¥4.61 loss per share (vs JP¥5.22 loss in 1Q 2021)

Solasia Pharma K.K. announced that it has received ¥3.94289 billion in funding from Macquarie Group Limited

Solasia Pharma K.K. announced that it has received ¥3.94289 billion in funding from Macquarie Group Limited

Solasia Pharma K.K. to Report Q3, 2022 Results on Nov 11, 2022

Solasia Pharma K.K. announced that it expects to receive ¥3.44289 billion in funding from Macquarie Group Limited

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Solasia Pharma K.K., Annual General Meeting, Feb 24, 2022

Third quarter 2021 earnings released: JP¥5.46 loss per share (vs JP¥5.71 loss in 3Q 2020)

Second quarter 2021 earnings released: JP¥5.67 loss per share (vs JP¥6.36 loss in 2Q 2020)

Solasia Pharma K.K. Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan

First quarter 2021 earnings released: JP¥5.22 loss per share (vs JP¥4.54 loss in 1Q 2020)

Full year 2020 earnings released: JP¥35.16 loss per share (vs JP¥17.75 loss in FY 2019)

Solasia Pharma K.K. to Report Q1, 2021 Results on May 12, 2021

New 90-day high: JP¥158

Full year 2020 earnings released: JP¥35.16 loss per share (vs JP¥17.75 loss in FY 2019)

Solasia Pharma K.K., Annual General Meeting, Mar 29, 2021

Solasia Pharma K.K. to Report Fiscal Year 2020 Results on Feb 16, 2021

Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Year Ending December 31, 2020

New 90-day low: JP¥123

Solasia Pharma K.K. announced that it expects to receive ¥13.44 million in funding from Macquarie Group Limited

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi